JP2018188571A - Antiviral inner package sheet - Google Patents

Abstract

An object of the present invention is to provide a polyvinyl chloride resin composition and an antiviral sheet having antiviral properties regardless of the presence or absence of a viral envelope.
SOLUTION: 0.1 to 10.0 parts by weight of a sulfonate surfactant, 10 to 50 parts by weight of a plasticizer, 1 to 1 part of an inorganic antiviral agent with respect to 100 parts by weight of a polyvinyl chloride resin. A polyvinyl chloride resin composition comprising 50 parts by weight.
[Selection figure] None

Description

  The present invention relates to an interior sheet excellent in antiviral properties and stain resistance.

  Viral diseases such as severe respiratory tract infection (SARS) virus, human and avian influenza virus, norovirus, foot-and-mouth disease virus, new influenza virus, etc. are becoming social problems one after another. Influenza viruses and noroviruses are viral infections that prevail in the winter, and it is said that more than 10 million people are affected each year. In addition, norovirus is very infectious, and it is said that even a very small amount (10 to 100) of virus can be infected. In order to prevent such viral infections as much as possible, antiviral products are expected not only for medical relations such as hospitals, health centers and nursing homes, but also for general public facilities and homes.

  Slaked lime is known as an antiviral agent capable of preventing the virus from entering cells by inactivating the infectivity of the virus. Patent Document 1 discloses a resin coating containing slaked lime. ing.

JP 2011-152102 A

Viruses include virus species having an envelope of a membranous structure and virus species having no envelope. A typical example of the former virus is an influenza virus, and an example of the latter is a norovirus. Since the envelope is made of lipid, the enveloped virus can be easily destroyed with alcohol or the like. However, viruses without envelopes are resistant to alcohol, so disinfectant solution is not effective. In the antiviral resin composition, there is a possibility that a difference in the antiviral properties occurs depending on the presence or absence of an envelope.
Therefore, in view of the above situation, an object of the present invention is to provide an antiviral polyvinyl chloride resin composition and an antiviral sheet that exhibit antiviral properties with or without an envelope.

In the present invention, 0.1 to 10.0 parts by weight of the sulfonate surfactant (B) and 10 to 50 parts by weight of the plasticizer (C) with respect to 100 parts by weight of the polyvinyl chloride resin (A). And a polyvinyl chloride resin composition containing 0.1 to 50 parts of an inorganic antiviral agent (H).
The sulfonate surfactant (B) may be added while being supported on the inorganic filler (D). In this case, the added amount is a polyvinyl chloride resin in which the inorganic filler supported at a weight ratio B: D of 1:20 to 1: 1 of the sulfonic acid surfactant (B) and the inorganic filler (D) is 1:20 to 1: 1. (A) A polyvinyl chloride-based resin composition having 0.1 to 200 parts by weight per 100 parts by weight.
Further, the polyvinyl chloride resin (A) is made of 100% to 1% by weight of a vinyl chloride resin for paste containing the sulfonate surfactant (B) and 0 to 99% by weight of the suspension vinyl chloride resin. This is a vinyl chloride resin composition.
Moreover, it can be set as the antiviral vinyl chloride resin sheet obtained by shape | molding these antiviral vinyl chloride resin compositions.

  According to the present invention, an antiviral vinyl chloride resin composition and an antiviral sheet excellent in antiviral properties can be obtained regardless of the presence or absence of an envelope.

Hereinafter, the present invention will be described in detail.
As an embodiment of the present invention, 0.1 to 10.0 parts by weight of the sulfonate surfactant (B) and 10 parts of the plasticizer (C) with respect to 100 parts by weight of the polyvinyl chloride resin (A). An antiviral polyvinyl chloride resin composition containing -50 parts by weight and 0.1-50 parts by weight of an inorganic antiviral agent (H).

  The polyvinyl chloride resin (A) used for the antiviral polyvinyl chloride resin composition is a thermoplastic resin mainly composed of vinyl chloride, but may contain a copolymer component other than vinyl chloride. . The amount of the copolymer component other than vinyl chloride is not particularly limited as long as it does not affect the present invention, but the content of the copolymer monomer component is 0 to 30 mol% in the total monomer components. It is preferable that it is 0-10 mol%. Specifically, polyvinyl chloride, ethylene-vinyl chloride copolymer, propylene-vinyl chloride copolymer, vinyl chloride-acrylic resin copolymer, vinyl chloride-urethane copolymer, vinyl chloride-vinylidene chloride copolymer And vinyl chloride-vinyl acetate copolymer. These polyvinyl chloride resins (A) may be used alone or in combination of two or more. Among these polyvinyl chloride resins (A), polyvinyl chloride is preferable in terms of processability and cost.

  The average degree of polymerization of the polyvinyl chloride-based resin (A) is not particularly limited as long as it can be substantially molded. However, the average degree of polymerization is preferably in the range of 500 to 2000, and the average degree of polymerization is 700. The range of ˜1800 is more preferable. If the average degree of polymerization is less than 500, it is difficult to process because the viscosity at the time of melting is low.

The sulfonate surfactant (B) is a sulfonate surfactant and a sulfate surfactant. Specifically, alkyl sulfate salts such as sodium lauryl sulfate, alkyl benzene sulfonates such as sodium dodecylbenzene sulfonate, alkyl naphthalene sulfonates such as sodium octyl naphthalene sulfonate, alkyl diphenyl ether disulfonates, polyoxyethylene alkyl sulfates Examples include ester salts and naphthalenesulfonic acid formalin condensates. Alkyl benzene sulfonate is preferable because of its high antiviral effect, and dodecyl benzene sulfonate is more preferable.
The content of the sulfonate surfactant (B) used in the present invention is preferably 0.1 to 10.0 parts by weight with respect to 100 parts by weight of the polyvinyl chloride resin (A), and 1.0 to 5.0 parts by weight is more preferable, and 2.0 to 3.0 parts by weight is particularly preferable. When the content is less than 0.1 parts by weight, the antiviral effect is poor, and when the content exceeds 10 parts by weight, the processability is poor, and the surface condition is poor due to bleeding, which may easily cause contamination.

  When the sulfonate surfactant (B) is added to the polyvinyl chloride resin (A) and molding is performed, the polyvinyl chloride resin may be colored.

  Regarding the above problem, the vinyl chloride resin (Ab) for paste to which the sulfonate surfactant (B) is added in advance is used, or the inorganic salt on which the sulfonate surfactant (B) is supported. By using the filler, coloring of the resin can be effectively suppressed.

  The vinyl chloride resin (Ab) for paste is a fine polymer particle having a particle size of 0.02 to 20.0 μm, which is mainly obtained by an emulsion polymerization method or a microsuspension polymerization method. It is a common feature that it becomes a paste.

  As a method for producing the vinyl chloride resin (Ab) for paste, any production method can be used as long as the vinyl chloride resin (Ab) for paste of the present invention can be obtained. As a method, emulsion polymerization is performed by using a vinyl chloride monomer together with deionized water, an emulsifier and a water-soluble polymerization initiator under gentle stirring, and emulsion polymerization is performed using particles obtained by the emulsion polymerization method as a seed. Seed emulsion polymerization method, vinyl chloride monomer is mixed with deionized water, emulsifier, emulsification aid such as higher alcohol, if necessary, oil-soluble polymerization initiator is mixed and dispersed with homogenizer, etc., and then polymerized under gentle stirring The polymerization temperature is increased to 30 to 80 ° C. by a micro-suspension polymerization method, a seed micro-suspension polymerization method in which polymerization is performed using a seed containing an oil-soluble polymerization initiator obtained by the micro-suspension polymerization method. Polymerized, after spray drying the resulting latex can be mentioned a method of making a paste vinyl chloride resin (Ab) by grinding.

  In the production of the vinyl chloride resin (Ab) for paste, a dispersant is used in order to enable smooth pulverization after spray drying. By using the sulfonate surfactant (B) as the dispersant, the sulfonate surfactant (B) is in a finely dispersed state, so that coloring of the resin can be suppressed.

  The content of the sulfonate surfactant (B) is preferably 0.1 to 15% by weight, more preferably 0.7 to 10% by weight in the polyvinyl chloride resin (Ab) for paste, and 1.0 to 7.5% by weight is particularly preferred. If it is less than 0.1% by weight, the antiviral property when it is used as an interior sheet is poor, and if it exceeds 15% by weight, the productivity in producing vinyl chloride resin (Ab) for paste becomes poor.

  The average degree of polymerization of the polyvinyl chloride resin (Ab) for paste is not particularly limited as long as it can be substantially molded, but the average degree of polymerization is preferably in the range of 500 to 2000, and the average degree of polymerization is preferred. A range of 700 to 1800 degrees is more preferable. If the average degree of polymerization is less than 500, it is difficult to process because the viscosity at the time of melting is low, and if the average degree of polymerization exceeds 2000, the viscosity at the time of melting may be high, which may make it difficult to process.

  When the polyvinyl chloride resin for paste (Ab) is used, if a liquid such as a plasticizer is mixed due to the characteristics of the polyvinyl chloride resin for paste, the paste becomes a paste at room temperature, and the processing method is limited to the coating method or the like. When the resin composition is molded by a melt shaping method in which the resin composition is heated and melted, kneaded, shaped and then cooled and solidified, it is preferably blended with a suspension vinyl chloride resin (Aa).

  Here, the suspension vinyl chloride resin vinyl chloride resin (Aa) is a porous amorphous vinyl chloride resin having a particle diameter of 50 to 200 μm and obtained mainly by suspension polymerization. By having such a porous shape, a liquid such as a plasticizer can be absorbed, so that a paste can be prevented.

  The blend ratio of the vinyl chloride resin for paste (Ab) and the suspension vinyl chloride resin (Aa) is 0.1 to 10.0% by weight of the sulfonate surfactant (B), and molding processing is a problem. Unless otherwise specified, the vinyl chloride resin (Ab) for paste is preferably 100 to 1% by weight, and the suspension vinyl chloride resin (Aa) is preferably 0 to 99% by weight. (Ab) is 70 to 10% by weight, suspension vinyl chloride resin (Ab) is more preferably 30 to 90% by weight, paste vinyl chloride resin (Ab) is 50 to 20% by weight, suspension vinyl chloride resin (Aa ) 50-80% by weight is most preferred.

  The average degree of polymerization of the suspension polyvinyl chloride resin (Aa) is not particularly limited as long as it can be practically molded, but a range of an average degree of polymerization of 500 to 2000 is preferable. The range of 700 to 1800 degree of polymerization is more preferable. If the average degree of polymerization is less than 500, it is difficult to process because the viscosity at the time of melting is low.

  The surfactant-carrying filler (E) carrying the sulfonate surfactant (B) is a surface-treated sulfonate surfactant (B) on the surface of the inorganic filler (D). is there.

There is no restriction | limiting in particular as an inorganic filler (D) which surface-treats a sulfonate surfactant (B), A general thing can be used. Examples thereof include calcium carbonate, silica, talc, mica, clay, diatomaceous earth, alumina, titanium oxide, magnesium hydroxide, zinc oxide, calcium silicate, and aluminum hydroxide, and these can be used alone or in combination. From the viewpoint of cost and supply, calcium carbonate and silica are preferable, and calcium carbonate is more preferable.
Moreover, as the inorganic filler (D), an inorganic filler (D) subjected to surface treatment for the purpose of improving the compatibility with the synthetic resin may be used. Examples of the surface treatment agent include fatty acids, silicic acid, phosphoric acid, and silane coupling agents. Examples of the fatty acid include saturated or unsaturated fatty acids having 6 to 31 carbon atoms, preferably 12 to 28 carbon atoms.

  As a method of supporting the sulfonate surfactant (B) on the inorganic filler (D), a method of spraying and drying an aqueous solution of the sulfonate surfactant (B) on the inorganic filler (D), There is a method in which an inorganic filler (D) is added to and mixed with an aqueous solution of a sulfonic acid-based surfactant to remove moisture and dried, and the remaining solid content is ground with a known pulverizer such as a ball mill.

  The weight ratio B: D between the sulfonate surfactant (B) and the inorganic filler (D) is preferably 1:20 to 1: 1, and preferably 1:10 to 1: 1. More preferred. When the ratio of the sulfonate surfactant (B) is smaller than 1:20 of the weight ratio B: D, the sulfonate surfactant (B) is difficult to be uniformly supported and has antiviral properties when added. If the ratio of the sulfonate surfactant (B) is greater than 1: 1 of the weight ratio B: D, it is excessively supported on the surface of the inorganic filler (D), and may be caused by moisture. Since it becomes a lump, dispersibility may deteriorate and surface defects may occur during processing.

  Next, 0.1 to 50 parts by weight of an inorganic antiviral agent (H) is contained with respect to 100 parts by weight of the polyvinyl chloride resin (A) for developing antiviral properties regardless of the presence or absence of an envelope. This is very important.

The antiviral polyvinyl chloride resin composition containing the sulfonate surfactant (B) exhibits an antiviral effect in a short time against viruses such as avian influenza virus, which is an enveloped virus. However, it tends to be difficult to show sufficient performance in a short time against viruses such as feline calicivirus which are viruses having no envelope.
On the other hand, the inorganic antiviral agent (H) shows an antiviral effect in a short time against feline calicivirus which is a virus having no envelope, but in a short time against avian influenza virus which is a virus having an envelope. It tends to be difficult to show sufficient effects.

  Here, by adding both the sulfonate surfactant (B) and the inorganic antiviral agent (H) to the vinyl chloride resin, the antiviral properties are exhibited in a short time regardless of the presence or absence of the envelope. An antiviral polyvinyl chloride resin composition can be obtained.

  Examples of the inorganic antiviral agent (H) include a photocatalyst, a metal compound, and an inorganic compound. Examples of the photocatalyst include a complex in which copper, iron, or the like is supported on titanium oxide, tungsten oxide, or the like. Examples of the metal compound include a combination of a compound containing silver ions or the like and a metal ion and a porous inorganic material such as zeolite, silica gel, or diatomaceous earth. Examples of the inorganic compound include calcium hydroxide such as slaked lime and dolomite. The inorganic antiviral agent (H) to be used may be used alone or in combination of a plurality of types.

  The addition amount of the inorganic antiviral agent (H) is 0.1 to 50 parts by weight with respect to 100 parts by weight of the polyvinyl chloride resin (A). If the added amount of the inorganic antiviral agent (H) is 50 parts by weight or more, the processability is remarkably lowered, and if it is less than 0.1 parts by weight, there are problems such as insufficient antiviral properties. The addition amount that provides satisfactory processability and antiviral properties as the antiviral polyvinyl chloride resin composition is 0.1 to 50 parts by weight, preferably 1 to 10 parts by weight.

Antiviral properties can be enhanced by increasing the amount of sulfonate surfactant (B) or inorganic antiviral agent (H), and there is a possibility that high antiviral properties can be obtained regardless of the presence or absence of an envelope. is there. However, if the addition amount of the sulfonate surfactant (B) is excessively increased, the thermal stability during processing of the polyvinyl chloride resin is lowered, and problems such as plate-out to the processing machine are likely to occur. Moreover, if the amount of the inorganic antiviral agent (H) added is excessively increased, the processability of the polyvinyl chloride resin composition may be deteriorated, or the mechanical properties and transparency of the molded product may be inferior to the desired performance. is there. Further, the photocatalyst and the silver-based inorganic antiviral agent (H) are generally expensive, which is not preferable because the cost of the polyvinyl chloride resin composition to which these are added is increased.
Therefore, instead of adding a high amount of the sulfonate surfactant (B) or the inorganic antiviral agent (H), the sulfonate surfactant (B) and the inorganic antiviral agent (H) By using together, high antiviral properties can be obtained regardless of the presence or absence of the envelope.

  As the plasticizer (C), a normal plasticizer can be used. For example, phthalate plasticizers such as DOP (di-2-ethylhexyl phthalate), DINP (diisononyl phthalate), DIDP (diisodecyl phthalate), dioctyl terephthalate (DOTP), DOA (di-2-ethylhexyl adipate), DIDA (Diisodecyl adipate) and other adipic acid ester plasticizers, DOS (di-2-ethylhexyl sebacate) and other sebacic acid ester plasticizers, and azelaic acid ester plasticizers such as DOZ (di-2-ethylhexyl azelate) Aliphatic dibasic acid ester plasticizers, such as tricresyl phosphate, trixylenyl phosphate, cresyl diphenyl phosphate, tris (isopropylated phenyl) phosphate tris (dichloropropyl) phosphate ester plasticizers, Riesuteru plasticizers, epoxy plasticizers, and the like sulfonate ester plasticizer. Examples thereof include a phthalate plasticizer having good compatibility with a vinyl chloride resin and a polyester plasticizer having a high molecular weight. The plasticizer (C) may be used alone or in combination of a plurality of types.

  The addition amount of the plasticizer (C) is preferably 10 to 50 parts by weight with respect to 100 parts by weight of the polyvinyl chloride resin (A). When the addition amount of the plasticizer (C) exceeds 50 parts by weight, it tends to be in a paste form, and the handling property of the resin composition before heating and melting may be inferior. If it is less than 10 parts by weight, processing may be difficult. The amount of the plasticizer (C) added is preferably 10 to 40 parts by weight, and more preferably 20 to 40 parts by weight.

  Filler (I) can be added to the antiviral polyvinyl chloride resin composition for the purpose of improving processability. Filler (I) includes calcium carbonate, silica, plate-like fillers such as talc and mica, clays such as bentonite and calcined kaolin, metal oxides such as magnesium oxide and alumina, magnesium hydroxide, aluminum hydroxide and the like. Inorganic fillers such as metal hydroxides can be used. In order to enhance the affinity with the vinyl chloride resin, the filler (I) may be subjected to various surface treatments such as fatty acids and modified fatty acids.

  The addition amount of the filler (I) is preferably 1 to 100 parts by weight with respect to 100 parts by weight of the polyvinyl chloride resin (A). When the added amount of the filler (I) exceeds 100 parts by weight, the smoothness of the surface of a molded body such as a sheet obtained by molding the antiviral polyvinyl chloride resin composition may be inferior. On the other hand, if the amount is less than 1 part by weight, the effect of improving workability may not be obtained. The amount of filler (I) added is preferably 5 to 30 parts by weight, and more preferably 10 to 20 parts by weight. When transparency is required, the amount of filler (I) added is preferably 1 to 5 parts by weight.

An acrylic polymer processing aid is preferably added to the interior sheet for the purpose of improving processability. Examples of the acrylic polymer processing aid include acrylic polymer processing aids such as methyl methacrylate-alkyl acrylate copolymers such as methyl methacrylate-butyl acrylate copolymers.
By adding an acrylic polymer processing aid, the rotational flow and degassing in the bank during roll molding and calendar molding are improved, and plate-out is suppressed, so that a sheet having a good appearance can be obtained.

In order to further prevent coloring during processing of the antiviral polyvinyl chloride resin composition, an anion of an inorganic compound containing β diketones and elements of Groups 13, 15 and 17 of the periodic table; In addition, it is preferable to add a coloring inhibitor comprising a combination of cations of elements of Groups 1, 2 and 12 of the periodic table, and among these, a perchlorate-based coloring inhibitor is particularly preferred. .
Perchlorate anti-coloring agents include lithium perchlorate, sodium perchlorate, potassium perchlorate, strontium perchlorate, magnesium perchlorate, calcium perchlorate, barium perchlorate, perchloric acid Ammonium etc. are mentioned. Of these, sodium perchlorate and potassium perchlorate are preferably used. These perchlorates may be anhydrous or hydrated salts, and may be those dissolved in alcoholic and esteric solvents such as butyl diglycol and butyl diglycol adipate and their dehydrates. Alternatively, perchloric acid-containing hydrotalcite obtained by treating hydrotalcite with perchloric acid may be used.
The addition amount of the coloring inhibitor is preferably 0.1 to 0.5 parts by weight with respect to 100 parts by weight of the polyvinyl chloride resin (A).

  If necessary, stabilizers, antioxidants, UV absorbers, light stabilizers, UV shielding agents, antistatic agents, flame retardants, thickeners, surfactants, fluorescent agents, crosslinking agents, impact modifiers Other compounding agents generally added to the resin may be added.

  Antiviral polyvinyl chloride resin composition is prepared by mixing polyvinyl chloride resin (A), sulfonate surfactant (B) and inorganic antiviral agent (H) using known production equipment. Can be manufactured. For example, as a polyvinyl chloride resin (A), a vinyl chloride resin (Ab) for paste, a suspension vinyl chloride resin (Aa), a sulfonate surfactant (B), and an inorganic antiviral agent (H) Can be produced by uniformly mixing with a high speed stirrer, a low speed stirrer, a Henschel mixer, a ribbon blender or the like. Further, the mixture obtained by mixing may be melt-mixed with a batch kneading mixer, a Banbury mixer, a kneader, an extruder, or the like and immediately molded. Moreover, after melt mixing, it may be once pelletized and then molded. In addition, additives, such as a plasticizer (C), a stabilizer, a filler (I), can be arbitrarily added according to each use.

Here, in the case of adding the sulfonate surfactant (B) in the production stage of the vinyl chloride resin (Ab) for paste, the chloride for paste to which the sulfonate surfactant (B) is added. By mixing the vinyl resin (Ab), the suspension vinyl chloride resin (Aa) and the inorganic antiviral agent (H), an antiviral polyvinyl chloride resin composition can be obtained.
On the other hand, when the surfactant-supporting filler (E) supporting the sulfonate surfactant (B) is used, the suspension vinyl chloride resin (Aa) and the sulfonate surfactant (B) are used. An antiviral polyvinyl chloride resin composition can be obtained by mixing the supported surfactant-carrying filler (E) and the inorganic antiviral agent (H).
Moreover, it may be dissolved and mixed in the same manner as above, or may be pelletized.

  An antiviral polyvinyl chloride resin composition can be obtained by melt-forming the antiviral polyvinyl chloride resin composition. For example, a melt molding method such as a roll molding method, a calendar molding method, an extrusion molding method, and a press molding method, a coating method, and the like can be given. From the viewpoint of speed and thickness accuracy of the obtained sheet, a melt shaping method is preferred, and among these, a calender molding method is preferred.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited to these Examples.

Specific substance names of each compounding agent used in Examples and Comparative Examples are as follows.
Polyvinyl chloride resin Aa-1: Suspension vinyl chloride resin (Aa) Average polymerization degree 1000
(Product name: TH-1000, manufactured by Taiyo PVC Co., Ltd.)
Polyvinyl chloride resin Ab-1: Vinyl chloride resin for paste (Ab) Average polymerization degree 850
(Na alkylbenzene sulfonate 5.0% by weight)
Sulfonate surfactant B-1: Alkylbenzene sulfonate Na purity 90%
(Product name: NANSA HS90 / S, manufactured by Huntsman Japan)
Plasticizer C-1: Di-2-ethylhexyl phthalate Inorganic filler D-1: Heavy calcium carbonate Carrier E-1: B: D = 1: 3
Stabilizer F-1: Ba-Zn metal soap Color inhibitor G-1: Sodium perchlorate (trade name; ADK STAB CPL-46, manufactured by Asahi Denka Kogyo Co., Ltd.)
Inorganic antiviral agent H-1: titanium oxide + copper compound photocatalyst (trade name; Lumiresh CT-2, manufactured by Showa Denko KK)
Inorganic antiviral agent H-2: Silver ion + zeolite complex (trade name: Zeomic, manufactured by Sinanen)
Inorganic antiviral agent H-3: Silver ion complex (trade name: PBM-H7, manufactured by MIC)
Inorganic antiviral agent H-4: calcined calcium hydroxide (trade name; Scarlow, manufactured by Antibacterial Research Laboratories)
Inorganic antiviral agent H-5: Dolomite (trade name; light dolomite, Yoshizawa Lime Industry Co., Ltd.)
Filler I-1: Light calcium carbonate (fatty acid treatment)
(Product name: TP-111, manufactured by Okutama Kogyo Co., Ltd.)

  Surfactant-carrying filler (E) is prepared by adding inorganic filler (D) to a 50 wt% aqueous solution of sulfonate-based surfactant (B), stirring, evaporating water, and using a mortar to remove the remaining solids. It was made by grinding.

  The formulations of Examples and Comparative Examples shown in Tables 1 to 4 were kneaded for 5 minutes with a batch mixer set at 150 ° C. Then, it shape | molded in the sheet form of thickness 0.35mm with the two rolls set to 180 degreeC, and produced the sheet | seat made from a vinyl chloride-type resin. Each vinyl chloride resin sheet was evaluated for antiviral properties, processability and yellowness.

<Antiviral properties>
Test virus J-1: Avian influenza virus A / whisling swan / Shimane / 499/83 (H5N3) strain. (Virus with envelope)
Test virus J-2: Feline calicivirus F9 strain. (Virus without envelope)

  The vinyl chloride resin sheet 5 cm × 5 cm prepared in the examples and comparative examples described in Tables 1 to 4 is placed in a petri dish, and 0.2 ml of the test virus solution is placed on the surface of the vinyl chloride resin sheet, 4 cm × 4 cm polyethylene film was covered, the petri dish was covered, and allowed to stand in an incubator set at 20 ° C. for an arbitrary time. After standing, the virus solution on the surface of the vinyl chloride resin sheet was collected and the virus titer was measured.

In the test for avian influenza virus, 0.1 ml of the virus solution was inoculated into the chorioallantoic cavity of 10-day-old chicken eggs, and the cultured chicken eggs were cultured at 37 ° C. for 2 days. The presence or absence of virus growth was determined by the hemagglutination test. Antiviral properties were evaluated based on the virus titer calculated by the Reed & Muench method (chicken fetal 50% infectious dose (log EID50 / 0.2 ml)).
In the test for feline calicivirus, the virus titer (PFUlog / 0.1 ml) calculated by the plaque method was used.
Moreover, the virus titer of the test virus solution before the test (before contacting with the vinyl chloride resin sheet) as a blank was also calculated in the same procedure as each test method. The antiviral property of the vinyl chloride resin sheet is evaluated by the virus titer reduction value. The virus titer reduction value is calculated by the following formula.
"Virus titer decrease value" = "virus titer before test"-"virus titer after test"
Here, it shows that antiviral property is so strong that a virus titer reduction value is large.

◎: Virus titer decrease value = 4 or more ○: Virus titer decrease value = 3-4
Δ: Virus titer decrease value = 1-3
X: Virus titer decrease value = 1 or less

<Processability>
The roll processability when the sheet was formed with two rolls set at 180 ° C. was evaluated.
◎: Good ○: Can be processed without problems △: Somewhat bad, but processing is possible ×: Processing is impossible

<Yellowness>
The yellowness was determined according to JIS K 7373 using “SM Color Computer” manufactured by Suga Test Instruments Co., Ltd.

  As is clear from Tables 1 to 4 above, antiviral properties are imparted regardless of the presence or absence of the envelope by simultaneously adding the sulfonate surfactant (B) and the inorganic antiviral agent (H). You can see that

According to the present invention, since it has high antiviral properties regardless of the presence or absence of a virus envelope, it is a hospital, nursing facility, nursing home, school, kindergarten, public hall, station, house, apartment, etc. It can be used for building materials made of vinyl chloride resin such as wallpaper, flooring, ceiling material, curtains and handrails. In addition, the antiviral polyvinyl chloride resin composition is processed into a sheet and then subjected to secondary processing such as cutting, heat welding, or solvent welding to provide protective clothing, protective clothing, protective apron, hat, gloves, foot cover, rain It can also be processed into a shape such as a coat.
In addition, as a preparation for the occurrence of a pandemic, it can be used as an interior sheet for a protective garment for protection, a protective garment, and a tent for exothermic outpatients, infectious diseases, or splash infection.

Claims (5)

  0.1 to 10 parts by weight of sulfonate surfactant (B), 10 to 50 parts by weight of plasticizer (C), and inorganic antiviral to 100 parts by weight of polyvinyl chloride resin (A) An antiviral polyvinyl chloride resin composition comprising 1 to 50 parts by weight of an agent (H). The sulfonate surfactant (B) is supported on the inorganic filler (D) at a ratio of B: D = 1: 20 to 1: 1 with respect to 100 parts by weight of the polyvinyl chloride resin (A). The antiviral polyvinyl chloride resin composition according to claim 1, wherein the surfactant-containing filler (E) is contained in an amount of 0.1 to 200 parts by weight.   Paste vinyl chloride resin (Ab) 100-1 in which the polyvinyl chloride resin (A) contains 0 to 99% by weight of suspension vinyl chloride resin (Aa) and the sulfonate surfactant (B). The antiviral polyvinyl chloride resin composition according to claim 1 or 2, comprising: wt%.   The polyvinyl chloride according to any one of claims 1 to 3, further comprising 1 to 50 parts by weight of a filler (I) with respect to 100 parts by weight of the polyvinyl chloride resin (A). Vinyl resin composition.   An antiviral vinyl chloride resin sheet formed using the antiviral vinyl chloride resin composition according to any one of claims 1 to 4.